Slides on Key Decisions in HIV Care: Choosing Initial ART in PWH With Transmitted Drug Resistance

Learn data and recommendations for initiating ART in a patient with transmitted antiretroviral drug resistance.
John D. Baxter, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 407 KB
Released: January 24, 2022

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Christine Katlama discusses minimizing ART exposure with dual-therapy and intermittent dosing strategies, from Clinical Care Options (CCO)

person default Christine Katlama, MD Released: January 4, 2023

Expert HIV faculty analyze new data from AIDS 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Princy N. Kumar, MD, FIDSA, MACP person default Mary W. Montgomery, MD David A. Wohl, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Dr Babafemi Taiwo discusses the emergence of lenacapavir for the treatment of multidrug-resistant HIV, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: December 19, 2022

Joseph Eron、Karine Lacombe、Chloe Orkin 和 Babafemi Taiwo 博士关于 IDWeek 和 HIV Glasgow 2022 的 HIV 数据的可下载幻灯片

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings